Surgical tactics for the treatment of subpleural and intra-pulmonary hematomas as a result of pneumonia caused by COVID-19
BACKGROUND. In December 2019, cases of pneumonia of unknown etiology were detected in Wuhan (China), and later a new type of coronavirus was identified – SARS-CoV-2. In March 2020, spread of the SARS-CoV-2 was officially recognized as a pandemic.
OBJECTIVE. To demonstrate to the doctors of the thoracic surgery and pulmonology departments our experience in the tactics of treating subpleural and intrapulmonary hematomas, which is a consequence of a coronavirus infection, and determining the need for surgical intervention.
MATERIALS AND METHODS. From the beginning of the COVID-19 pandemic on the basis of the clinical department of the surgical treatment of tuberculosis and non-specific diseases complicated by purulent-septic infections of the SI “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the NAMS of Ukraine” treated 11 patients with spontaneous hematomas of post-COVID genesis, of which subpleural hematomas accounted for 9 cases (81.8 %), and intrapulmonary – 2 (18.2 %). The distribution by gender was as follows: 7 (63.6 %) women were treated, and 4 (36.4 %) men. The age of the patients ranged from 28 to 70 years, the average age was 45 years. This group of patients had the following associated pathologies: chronic obstructive pulmonary disease – 3 (27.3 %), hypertension – 3 (27.3 %), diabetes – 2 (18.2 %), chronic renal failure – 1 (9.0 %), ischemic heart disease – 2 (18.2 %).
CONCLUSIONS. Lack of timely diagnosis and surgical treatment of subpleural and intrapulmonary hematomas often leads to the addition of secondary infection, which complicates the treatment process.
Opanasenko M.S., et al. Surgical treatment of broncho-pulmonary purulent-inflammatory complications due to permanent coronavirus infection – the first experience. Tuberculosis, Lung Diseases, HIV Infection. 2021; 3: 7-14. doi: 10.30978/TB-2021-3-7.
Opanasenko M.S., et al. Surgical treatment of thoracic pathology in patients with coronavirus infection. Ukrainian Pulmonology Journal. 2021; 3: 31-35. doi: 10.31215/2306-4927-2021-29-3-31-35.
Feshchenko Yu., et al. Lung lever after COVID-19: clinical-X-ray, surgical and morphological characteristics. Infusion & Chemotherapy. 2022; 1: 7-15. doi: 10.32902/2663-0338-2022-1-7-15.
Lake M.A. What we know so far: COVID-19 current clinical knowledge and research. Clin. Med. 2020 Mar 5; 20 (2): 124-7.
Duggal M., Dahiya N., Kankaria A., Chaudhary M., Bachani D. Restructuring the healthcare system to protect healthcare personnel amidst the COVID-19 pandemic. Front. Public Health. 2020 Dec 11; 8: 588203. doi: 10.3389/fpubh.2020.588203.
Mohanty S.K., Satapathy A., Naidu M.M., Mukhopadhyay S., Sharma Sh., et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) – anatomic pathology perspective on current knowledge. Diagnostic Pathology. 2020 Aug 14; 15 (1): 103. doi: 10.1186/s13000-020-01017-8.
Singh D., Mathioudakis A.G., Higham A. Chronic obstructive pulmonary disease and COVID-19: interrelationships. Curr. Opin. Pulm. Med. 2022 Mar 1; 28 (2): 76-83. doi: 10.1097/MCP.0000000000000834.
Hojo M., Terada-Hirashima J., Sugiyama H. COVID-19 and bronchial asthma: current perspectives. Glob. Health Med. 2021 Apr 30; 3 (2): 67-72. doi: 10.35772/ghm.2020.01117.
Peng M., He J., Xue Y., Yang X., Liu S., Gong Z. Role of hypertension on the severity of COVID-19: a review. J. Cardiovasc. Pharmacol. 2021 Nov 1; 78 (5): e648-e655. doi: 10.1097/FJC.0000000000001116.
Liang C., Zhang W., Li S., Qin G. Coronary heart disease and COVID-19: a meta-analysis. Med. Clin. (Barc.). 2021 Jun 11; 156 (11): 547-554. doi: 10.1016/j.medcli.2020.12.017. Epub 2021 Jan 28.
Lim S., Bae J.H., Kwon H.S., et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat. Rev. Endocrinol. 2021; 17: 11-30. doi: 10.1038/s41574-020-00435-4.
Liu D., Zhang T., Wang Y., Xia L. The centrality of obesity in the course of severe COVID-19. Front. Endocrinol. (Lausanne). 2021 Mar 11; 12: 620566. doi: 10.3389/fendo.2021.620566.
Al-Jahdhami I., Al-Naamani K., Al-Mawali A., Bennji S.M. Respiratory complications after COVID-19. Oman. Med. J. 2022 Jan 31; 37 (1): e343. doi: 10.5001/omj.2022.52.
Liliana R., Joelma S., Cláudia Sofia P. Spontaneous pulmonary hematoma as a complication of anticoagulant therapy. Archivos de Bronconeumología. 2018; vol. 54, issue 10: 528-529. doi: 10.1016/j.arbres.2018.02.010.
Sebek J., Vodicka J., Procházková K., Kletecka J., Treska V. Massive intrathoracic haemorrhage as a complication of pulmonary parenchymal haemorrhage and anticoagulant treatment of lung embolization during COVID-19 – two case reports. Rozhl. Chir. 2022 Fall; 101 (9): 452-455. doi: 10.33699/PIS.2022.101.9.452-455.
This work is licensed under a Creative Commons Attribution 4.0 International License.